<DOC>
	<DOCNO>NCT00965588</DOCNO>
	<brief_summary>The purpose Phase I study determine whether vaccine ( UB 311 ) , target amyloid beta peptide ( N-terminal amino acid , 1-14 ) , safe immunogenic patient diagnose mild moderate Alzheimer 's disease ( AD ) . Amyloid beta select target antigen base support evidence hypothesis place accumulation amyloid beta initiate step AD .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability Immunogenicity Vaccine ( UB 311 ) Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Diagnosis mild moderate Alzheimer 's Disease MiniMental State Examination ( MMSE ) 1525 Other inclusion criterion apply Major psychiatric disorder Severe systemic disease Serious adverse reaction vaccine Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>amyloid beta</keyword>
	<keyword>vaccine</keyword>
</DOC>